[1] 潘国焰,陈金灶,林雪萍,等.小剂量达格列净联合沙库巴曲缬沙坦治疗慢性心力衰竭患者的疗效观察[J].心血管病防治知识,2023,13(12):23-25,29.
[2] 任宁,宋婷婷,周东红,等.医联体背景下中老年射血分数中间值急性心力衰竭住院患者的临床特征及预后[J].中华老年医学杂志,2022,41(1):5-10.
[3] Jhund P S, Solomon S D, Docherty K F, et al.Efficacy of dapagliflozin on renal function and outcomes in patients with heart failure with reduced ejection fraction: results of DAPA-HF[J]. Circulation, 2021, 143(4): 298-309.
[4] 刘杨,张娟,胡莹,等.芪苈强心胶囊联合左西孟旦注射液治疗老年急性心肌梗死合并左心衰竭患者临床观察[J].疑难病杂志,2023,22(4):350-355.
[5] 阮征,黄建玉,姜文才,等.射血分数中间值心力衰竭——究竟该如何认识?[J].中国全科医学,2022,25(5):522-529.
[6] 李丽,赵文萍.sST2联合NT-proBNP评估ARNI干预射血分数中间值的心力衰竭患者预后价值分析[J].中国循证心血管医学杂志,2021,13(1):85-89,93.
[7] Wheeler D C, Stefánsson B V, Jongs N, et al.Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial[J]. The lancet Diabetes & endocrinology, 2021, 9(1): 22-31.
[8] Xu X, Yang Y, Zhou G, et al.Clinical efficacy of qiliqiangxin capsule combined with western medicine in the treatment of chronic heart failure: a systematic review and meta-analysis[J]. Evidence-based Complementary and Alternative Medicine, 2021, 2021: 1-18.
[9] 王红伍,肖淑云,袁忠孝,等.SGLT2抑制剂联合芪苈强心胶囊对老年心功能指标的影响探讨[J].系统医学,2023,8(21):9-13.
[10] 丁明明,李芸蕊,郑芝欣,等.芪苈强心胶囊联合达格列净片对糖尿病合并心力衰竭患者氧化应激反应的影响[J].新中医,2022,54(9):85-89.
[11] 张玲娟,王西辉,曹彪,等.芪苈强心胶囊联合达格列净对心力衰竭合并2型糖尿病患者血糖水平、神经内分泌因子及心功能的影响[J].临床医学研究与实践,2022,7(20):61-65.
[12] 马建飞,刘宪桂,赵靖华,等.芪苈强心胶囊联合尼可地尔对射血分数保留性心力衰竭患者心功能及细胞因子的影响[J].广东医学,2023,44(3):379-382. |
